Sample size calculation (Pilot study result vs literature) [Power / Sample Size]

posted by Alyssa – Malaysia, 2020-05-04 11:26 (1533 d 18:26 ago) – Posting: # 21392
Views: 8,612

Dear Dr. Dan,

Thanks for your reply.

❝ I guess you are talking about an oral IR formulation, right?

Is a oral MR formulation.

❝ It is reasonable to assume that the ISCV in the pivotal study will be similar to the pilot study if you use the same CRO (study procedure performance), the same test formulation vs. the same (batch of) reference product and the same bioanalytical method.

The CRO we used for pilot study is the same as per the one used in the published literature (sponsor mentioned the CRO name in the PAR). Therefore, the study procedure performance and bioanalytical method variability is reduced.

❝ If costs do not matter you can of course follow the suggestion of the CRO to go for 4 way crossover, replicate design, with ratio 90-111%, ISCV = 35-40%. :-D:-D:-D

Cost is definitely a matter for us now, especially during this Covid-19 pandemic, have to spend wisely. Therefore i need some expert opinion here for my consideration. :confused:

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
 Admin contact
23,101 posts in 4,857 threads, 1,644 registered users;
86 visitors (0 registered, 86 guests [including 8 identified bots]).
Forum time: 05:53 CEST (Europe/Vienna)

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz